A major clinical trial investigating β-hydroxy β-methylbutyrate (HMB) as a potential treatment for liver cirrhosis has been launched across eight UK hospitals, supported by £500,000 from NIHR.

Phase 2 trial of anetumab ravtansine plus bevacizumab was terminated early after showing inferior progression-free survival compared to standard paclitaxel-bevacizumab combination in platinum-resistant ovarian cancer.

Clinical trial sponsors and CROs must establish optimal oversight balance, with experts warning that both excessive and insufficient monitoring can impede trial success and efficiency.

The Alzheimer's drug development landscape has expanded significantly beyond anti-amyloid antibodies, with 88 different clinical trials currently recruiting patients and twelve Phase 3 trials expected to report results in 2025.

The 12th Annual Outsourcing in Clinical Trials & Clinical Trial Supply Nordics meeting in Copenhagen will bring together experts to explore current trends in trial operations, outsourcing, and supply chain management.

Clinical trials utilizing artificial intelligence reached unprecedented levels in 2024, with major pharmaceutical companies like Roche and AstraZeneca implementing AI for patient recruitment and trial management.

Cilta-cel, a CAR T-cell therapy, significantly improved overall survival (OS) compared to standard-of-care regimens in patients with relapsed/refractory multiple myeloma.

The Patent Trial and Appeal Board has instituted a patent grant review (PGR) against Halozyme Therapeutics amid an ongoing patent infringement lawsuit with Merck & Co.

Myriad Genetics announced early access to the FirstGene Multiple Prenatal Screen, a comprehensive four-in-one genetic test that combines fetal aneuploidy screening, recessive disease screening, carrier screening, and RhD compatibility assessment in a single blood draw.

The FDA has granted Fast Track designation to Genascence's GNSC-001, a gene therapy for osteoarthritis (OA) of the knee, expediting its development and review.

A pooled analysis of the GLOW and CAPTIVATE-FD trials showed that first-line ibrutinib plus venetoclax led to overall survival (OS) rates similar to an age-matched general European population in CLL patients.

A phase III trial of ARX788 showed a significantly longer median progression-free survival (PFS) of 11.3 months compared to 8.2 months with lapatinib plus capecitabine (LC) in HER2-positive advanced breast cancer patients.

Moderna's mRNA-1769 vaccine demonstrated superior efficacy in preventing severe mpox disease compared to the Jynneos vaccine in a monkey model.

Independent Data Safety Monitoring Board recommends proceeding with Belite Bio's Phase 3 DRAGON trial of Tinlarebant for Stargardt disease without modifications, maintaining the original 104-subject sample size.

Tenaya Therapeutics reported initial data from its MyPEAK-1 trial, evaluating TN-201 gene therapy for MYBPC3-associated hypertrophic cardiomyopathy (HCM).

A phase I/II trial of atezolizumab combined with standard radiation and temozolomide achieved a median overall survival of 18.0 months in newly diagnosed glioblastoma patients, with particularly strong outcomes in those with high immune infiltration (24.8 months).

Novo Nordisk's amycretin, a GLP-1 and amylin receptor agonist, demonstrated significant weight loss in a Phase 1b/2a trial.

Pivekimab sunirine (PVEK), a first-in-class antibody-drug conjugate, demonstrated an 85% overall response rate and 70% complete response rate as frontline treatment for newly diagnosed BPDCN patients.

Lisocabtagene maraleucel (liso-cel) demonstrates efficacy and safety in second-line treatment of relapsed/refractory large B-cell lymphoma (LBCL), aligning with pivotal trial outcomes.

A phase II trial investigating hepatic artery infusion of FOLFOX chemotherapy plus camrelizumab combined with sorafenib in BCLC stage C hepatocellular carcinoma failed to meet its primary endpoint, showing a modest 44% objective response rate.